Alnylam Pharmaceuticals' Change in Accured Expenses rose 167.37% to $223.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $187.8 million, marking a year-over-year increase of 63.98%. This contributed to the annual value of $91.1 million for FY2024, which is 12.68% up from last year.
As of FY2024, Alnylam Pharmaceuticals' Change in Accured Expenses stood at $91.1 million, which was up 12.68% from $80.8 million recorded in FY2023.
In the past 5 years, Alnylam Pharmaceuticals' Change in Accured Expenses ranged from a high of $191.8 million in FY2022 and a low of $80.8 million during FY2023.
For the 3-year period, Alnylam Pharmaceuticals' Change in Accured Expenses averaged around $121.2 million, with its median value being $91.1 million (2024).
Per our database at Business Quant, Alnylam Pharmaceuticals' Change in Accured Expenses skyrocketed by 117.33% in 2022 and then crashed by 57.85% in 2023.
Over the past 5 years, Alnylam Pharmaceuticals' Change in Accured Expenses (Yearly) stood at $143.7 million in 2020, then slumped by 38.61% to $88.2 million in 2021, then skyrocketed by 117.33% to $191.8 million in 2022, then plummeted by 57.85% to $80.8 million in 2023, then grew by 12.68% to $91.1 million in 2024.

Peer Comparison

Historic Data

Download Data 🔒

Date	Value